Enguent Jean-Pierre 4

What Happened
Enguent Jean‑Pierre, Vice President, R&DSS at SEALSQ Corp (LAES), exercised option(s) on April 6, 2026 and subsequently sold shares on April 8, 2026. The filing shows a 15,000‑share exercise at $0.01 (cost $150, reported as acquired) and a separate 15,000‑share derivative line at $0.00 (reported as disposed). On April 8 he sold 15,000 shares in the open market for a weighted average price of $2.20, generating proceeds of $32,976.

Key Details

• Transaction dates: exercise(s) on 2026-04-06; sale on 2026-04-08. Form 4 filed 2026-04-09 (covers period of report 2026-04-06).
• Exercise(s): 15,000 shares @ $0.01 (acquired) and 15,000 shares @ $0.00 (reported as derivative disposed).
• Sale: 15,000 shares @ weighted avg $2.20 for $32,976 total; sale prices ranged from $2.13 to $2.42 per footnote.
• Footnotes: F1 — transactions were effected under a Rule 10b5-1 trading plan adopted Oct 13, 2025. F2 — weighted‑average sale price with per‑trade price range 2.13–2.42; the filer will provide per‑price breakdown on request.
• Shares owned after transaction: not specified in the supplied filing data.
• Timeliness: Form filed Apr 9, 2026 for activity on Apr 6 and Apr 8; Form 4s are typically due within two business days of the transaction — check the SEC filing page for any late‑filing flags if timeliness is a concern.

Context
The filing shows an option exercise (derivative code M) followed by an open‑market sale. The presence of a pre‑established Rule 10b5‑1 trading plan (per F1) indicates the sales were executed under a prearranged schedule. This is factual reporting of the transactions and does not, by itself, indicate the insider’s view of the company’s prospects.